• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

NVIDIA Makes Drug Discovery, Medical Imaging, and Genomics Easier with Cloud-Based AI

by Fred Pennic 05/03/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Harnessing the power of AI for healthcare just got simpler. NVIDIA announced the integration of NVIDIA NIM, a collection of cloud-native AI microservices, with Amazon Web Services (AWS). 

– The strategic collaboration empowers developers to leverage pre-trained AI models for drug discovery, medical imaging analysis, and genomics research – all accessible through user-friendly APIs.

Streamlined Access to Powerful AI Tools

NIM integrates seamlessly with popular AWS services like SageMaker (for machine learning model development) and ParallelCluster (for high-performance computing). Additionally, AWS HealthOmics, a specialized service for biological data analysis, can orchestrate NIM workflows. This integration simplifies the process of deploying cutting-edge AI models for healthcare and life sciences companies already using the AWS cloud infrastructure.

Benefits of NVIDIA NIM on AWS

  • Faster Development: Researchers can bypass complex model development and packaging, accelerating the deployment of generative AI solutions.
  • Multimodal Workflows: NIM facilitates the creation of workflows combining AI models from various sources, like protein sequences, medical images, and patient records.
  • Enhanced Drug Discovery: BioNeMo, a foundation for AI models in drug discovery, is included in NIM. Companies like Amgen are already utilizing BioNeMo to train protein design models.

Real-World Examples of Success

  • A-Alpha Bio: This company developing protein interaction prediction tools saw a 10x speedup by utilizing BioNeMo models optimized for NVIDIA GPUs on AWS.
  • Agilent: This life sciences leader used NVIDIA Parabricks, a genomics analysis tool within NIM, to significantly improve processing speeds for variant calling workflows.

Beyond Drug Discovery and Genomics

NIM offers more than just scientific applications. It also includes:

  • Large Language Models: These powerful language processing tools can be used to create conversational AI healthcare assistants for patient education and clinician support.
  • Visual Generative AI: This technology allows for the development of digital avatars and chatbots for a more engaging user experience.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |